Iloperidone

伊潘立酮

Report date: 2024/04/03 14:31:17
NME

Base Information

Drug NameIloperidone
Drug Alias Nameiloperidona伊洛哌酮伊洛培酮iloperidonumFanaptum +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderStress Disorders, Post-TraumaticSchizophrenia +[7] 
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/05/06
Country/TerritoryBulgariaUnited StatesUkraine +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesVanda Pharmaceuticals IncJewim Pharmaceutical (Shandong) Co LtdNanjing Huawe Medicine Technology Group Co Ltd +[4] 
Inactive CompaniesVanda Pharmaceuticals LtdNovartis Pharma AgJiangsu Hansoh Pharmaceutical Group Co Ltd +[6] 
Active IndicationsBipolar I DisorderSchizophreniaBipolar Disorder +[4] 
Inactive IndicationsStress Disorders, Post-TraumaticParkinson DiseaseHepatic Insufficiency

Other Information

ATC CodeN05AX14
Related LinksWikipediaDrugBankKEGG